Core Viewpoint - Ultragenyx Pharmaceutical Inc. will host a conference call on February 12, 2026, to discuss its financial results and corporate updates for the year ending December 31, 2025 [1]. Group 1: Company Overview - Ultragenyx is a biopharmaceutical company focused on developing and commercializing novel products for serious rare and ultra-rare genetic diseases [3]. - The company has established a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical needs [3]. - Ultragenyx's management team has extensive experience in the development and commercialization of therapeutics for rare diseases [4]. Group 2: Strategic Approach - The company's strategy emphasizes time- and cost-efficient drug development to deliver safe and effective therapies to patients urgently [4].

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is set to discuss its financial results and corporate updates for Q2 2025 on August 5, 2025, highlighting its focus on rare and ultra-rare genetic diseases [1]. Company Overview - Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases [3]. - The company has established a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with significant unmet medical needs [3]. - Ultragenyx's management team possesses extensive experience in the development and commercialization of therapeutics for rare diseases [4]. Strategic Focus - The company's strategy emphasizes time- and cost-efficient drug development to deliver safe and effective therapies to patients urgently [4].

Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases [3] - The company has established a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical needs [3] Management and Strategy - The management team of Ultragenyx is experienced in the development and commercialization of rare disease therapeutics [4] - The company's strategy emphasizes time- and cost-efficient drug development to deliver safe and effective therapies to patients urgently [4] Upcoming Events - Howard Horn, the chief financial officer and executive vice president of Ultragenyx, will participate in a fireside chat at Bank of America's 2025 Healthcare Conference on May 13, 2025, at 8:00 a.m. PT [1] - A live and archived webcast of the panel will be available on the company's website [2]

Core Viewpoint - Ultragenyx Pharmaceutical Inc. will host a conference call on May 6, 2025, to discuss its financial results and corporate updates for Q1 2025 [1]. Group 1: Company Overview - Ultragenyx is a biopharmaceutical company focused on developing and commercializing novel products for serious rare and ultra-rare genetic diseases [3]. - The company has established a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical needs [3]. - Ultragenyx's management team has extensive experience in the development and commercialization of therapeutics for rare diseases [4]. Group 2: Strategic Focus - The company's strategy emphasizes time- and cost-efficient drug development to deliver safe and effective therapies to patients urgently [4].